目的 探讨脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛的临床疗效。方法 选取2015年7月—2016年7月在达州市达川区人民医院进行治疗的不稳定型心绞痛患者64例，根据治疗方案的差别分为对照组（32例）和治疗组（32例）。对照组患者静脉滴注注射用二丁酰环磷腺苷钙，40 mg加入5%葡萄糖注射液250 mL，1次/d。治疗组在对照组的基础上口服脉血康胶囊，4粒/次，3次/d。两组患者均治疗4周。评价两组治疗后患者临床疗效，同时比较治疗前后两组患者心绞痛改善情况、氧化应激水平、血管内皮功能和炎性因子水平变化。结果 治疗后，对照组和治疗组的总有效率分别为81.25%、93.75%，两组总有效率比较差异有统计学意义（P < 0.05）。治疗后，两组患者心绞痛发作次数、发作持续时间、心电图ST段压低数和心电图T波总倒置数均较同组治疗前明显降低（P < 0.05）；且治疗组患者比对照组降低的更显著（P < 0.05）。与治疗前相比，治疗后两组血清丙二醛（MDA）水平显著降低，超氧化物歧化酶（SOD）活性显著升高，同组比较差异具有统计学意义（P < 0.05）；且治疗组上述指标改善的更显著（P < 0.05）。治疗后，两组患者血清内皮素-1（ET-1）水平明显降低，NO水平明显增高，同组比较差异具有统计学意义（P < 0.05）；且治疗后治疗组患者上述血管内皮功能优于对照组（P < 0.05）。治疗后，两组血清超敏C反应蛋白（hs-CRP）、白细胞介素-18（IL-18）、肿瘤坏死因子-α（TNF-α）水平均显著降低（P < 0.05）；且治疗后治疗组患者炎性因子水平比对照组更低（P < 0.05）。结论 脉血康胶囊联合二丁酰环磷腺苷治疗不稳定型心绞痛效果显著，可显著改善血管内皮功能和降低氧化应激反应，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Maixuekang Capsules combined with dibutyryladenosine cyclophosphate in treatment of unstable angina pectoris. Methods Patients (64 cases) with unstable angina pectoris in Dachuan District People's Hospital in Dazhou City from July 2015 to July 2016 were divided into control (32 cases) and treatment (32 cases) groups based on different treatments. Patients in the control group were iv administered with Calcium Dibutyryladenosine Cyclophosphate for injection, 40 mg added into 5% glucose injection 250 mL, once daily. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for four weeks. After treatment, the clinical efficacy was evaluated, and the angina pectoris improvement, oxidative stress levels, vascular endothelial function, and inflammatory factors levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.25% and 93.75% respectively, and there was difference between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris, ECG ST segment reduction, and the total number of ECG T wave inversion in two groups were significantly decreased (P < 0.05). And these indicators levels in the treatment group were significantly lower than those in the control group (P < 0.05). Compared with those before treatment, the MDA level in two groups was significantly decreased after treatment, but the SOD level was significantly increased, and there was difference in the same groups (P < 0.05). And these indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the ET-1 level in two groups was significantly decreased, the NO level was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the vascular endothelial function in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the hs-CRP, IL-18, and TNF-α levels in two groups were significantly decreased (P < 0.05). And these inflammatory factors levels in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Maixuekang Capsules combined with dibutyryladenosine cyclophosphate has significant clinical effect in treatment of unstable angina pectoris, can improve endothelial function and reduce oxidative stress reaction, which has a certain clinical application value.